logo

For the Inventor, By the Inventor

Ballerup, Denmark

Tina Møller Tagmose

This inventor holds 10 USPTO granted patents and 1 published patent application and 17 EPO patents. Top assignee: Novo Nordisk A/s. Active years: 2009-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tina Møller Tagmose. Retrieved from https://idiyas.com/inventor/tina-møller-tagmose

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 

% Patents Active = 50.0

 

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 40(Granted Patents)


Company Filing History:

goldMedal10 out of 1,803 
 
Novo Nordisk A/s
 patents

Years Active: 2009-2016

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 9480753 - FGF21 derivatives with albumin binder A-B-C-D-E- and their use (2016-11-01),
2. 9242011 - Insulin albumin conjugates (2016-01-26),
3. 9150633 - Insulin analogues with an acyl and alkylene glycol moiety (2015-10-06),
4. 8987197 - Protease stabilized, pegylated insulin analogues and uses thereof (2015-03-24),
5. 8828923 - Insulin derivatives (2014-09-09),
6. 8722620 - Insulin derivatives (2014-05-13),
7. 8710001 - PEGylated, extended insulins (2014-04-29),
8. 8637647 - Method of acylating a peptide or protein (2014-01-28),
9. 8476228 - Insulin derivatives (2013-07-02),
10. 7615532 - Insulin derivatives (2009-11-10),

Title: Innovations of Tina Møller Tagmose

Introduction

Tina Møller Tagmose is a prominent inventor based in Ballerup, Denmark. She has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative treatments for various metabolic disorders. With a total of 10 patents to her name, her work has had a substantial impact on the medical community.

Latest Patents

One of her latest patents involves Fibroblast Growth Factor 21 (FGF21) derivatives with an albumin binder. This invention relates to compounds that have an albumin binder of the formula A-B-C-D-E- covalently attached. The derivatives are designed to improve the treatment of conditions such as diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and Non-Alcoholic Fatty Liver Disease (NAFLD). These compounds are capable of maintaining low blood glucose levels for extended periods, increasing the in vivo half-life of FGF21, and improving oxidative stability. Another significant patent involves insulin albumin conjugates, which consist of an insulin analogue, a bifunctional linker, and albumin. These conjugates are effective in treating diabetic patients.

Career Highlights

Tina Møller Tagmose works at Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care and other chronic conditions. Her innovative research and development efforts have positioned her as a key figure in the advancement of therapeutic solutions.

Collaborations

Some of her notable coworkers include Peter Madsen and Thomas Hoeg-Jensen, who have collaborated with her on various projects within the pharmaceutical domain.

Conclusion

Tina Møller Tagmose's contributions to the field of pharmaceuticals through her innovative patents and research have made a significant impact on the treatment of metabolic disorders. Her work continues to inspire advancements in medical science and improve patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…